Patents Assigned to ID Biomedical Corporation
-
Patent number: 7410645Abstract: The present invention relates to polypeptides of Moraxella(Branhamella) catarrhalis which may be useful for prophylaxis, diagnosis and/or therapy purposes.Type: GrantFiled: May 15, 2002Date of Patent: August 12, 2008Assignee: ID Biomedical CorporationInventors: Denis Martin, Josée Hamel, Bernard R. Brodeur, Stéphane Rioux, Julie Couture
-
Patent number: 7410648Abstract: The present invention relates to polypeptides, more particularly polypeptides of Moraxella (Branhamella) catarrhalis which may be used to prevent, diagnose and/or treat Moraxella (Branhamella) catarrhalis infection.Type: GrantFiled: November 15, 2002Date of Patent: August 12, 2008Assignee: ID Biomedical CorporationInventors: Denis Martin, Josée Hamel, Bernard R. Brodeur, Stéphane Rioux, Julie Couture
-
Publication number: 20080175868Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.Type: ApplicationFiled: July 24, 2007Publication date: July 24, 2008Applicants: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical ResearchInventors: George H. Lowell, George L. White, Michael Raymond Batzloff, David S. Burt, Tomas B. Leanderson, Michael F. Good
-
Patent number: 7399840Abstract: Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.Type: GrantFiled: February 3, 2004Date of Patent: July 15, 2008Assignee: ID Biomedical Corporation of QuebecInventors: David S. Burt, David H. Jones, George H. Lowell, Gregory L. White, Kirkor Torossian, Louis F. Fries, III, Martin Plante
-
Patent number: 7393536Abstract: The present invention relates to antigens, more particularly antigens of Group B Streptococcus (GBS) (S. agalactiae) which may be useful to prevent, diagnose and/or treat streptococcal infections.Type: GrantFiled: July 5, 2002Date of Patent: July 1, 2008Assignee: ID Biomedical CorporationInventors: Denis Martin, Stéphane Rioux, Bernard R. Brodeur, Josée Hamel, Martine Boyer
-
Publication number: 20080124337Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 29, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20080124351Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 29, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20080124353Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 29, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20080107676Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 8, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20080107675Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 8, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20080107674Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 8, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7368537Abstract: The present invention relates generally to methods of treating or preventing RSV infections, and more specifically, to compositions, and the use thereof, comprising one or more RSV G protein immunogen or fragment thereof capable of eliciting protective immunity without eliciting an immunopathological response or eliciting a reduced immunopathological response.Type: GrantFiled: July 9, 2004Date of Patent: May 6, 2008Assignee: ID Biomedical Corporation of QuebecInventors: Robert Anderson, Yan Huang, David S. Burt
-
Patent number: 7335368Abstract: Group B streptococcus polypeptides and polynucleotides encoding them are disclosed. Said polypeptides may be useful for the prophylaxis, diagnostic and/or therapy of streptococcal infection in mammals. Also disclosed are recombinant methods of producing the polypeptide antigens as well as diagnostic assays for detecting streptococcal infections, particularly GBS.Type: GrantFiled: October 15, 2001Date of Patent: February 26, 2008Assignee: ID Biomedical CorporationInventors: Denis Martin, Stephane Rioux, Martine Boyer, Josée Hamel, Bernard R Brodeur
-
Publication number: 20080038268Abstract: The present invention relates to antigens, more particularly an antigen of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which is useful as vaccine component for therapy and/or prophylaxis.Type: ApplicationFiled: July 9, 2007Publication date: February 14, 2008Applicant: ID Biomedical CorporationInventors: Denis Martin, Josee Hamel, Bernard Brodeur, Stephane Rioux, Martine Boyer
-
Patent number: 7329500Abstract: The present invention relates to polypeptides of Moraxella (Branhamela) catarrhalis which may be used for prophy-laxis, diagnostic and/or therapy purposes.Type: GrantFiled: August 27, 2002Date of Patent: February 12, 2008Assignee: ID Biomedical CorporationInventors: Denis Martin, Josée Hamel, Bernard R. Brodeur, Stéphane Rioux, Julie Couture
-
Patent number: 7273611Abstract: The identification of a highly conserved, immunologically accessible antigen on the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoaea strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 6, 2000Date of Patent: September 25, 2007Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7270827Abstract: Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nucleic acids encoding such hybrid polypeptides. The hybrid polypeptide formulations may be used, for example, in methods for treating or preventing a microbial infection and eliciting a protective immune response having broadly protective opsonic antibodies in the absence of tissue cross-reactive antibodies.Type: GrantFiled: October 28, 2002Date of Patent: September 18, 2007Assignees: University of Tennessee Research Foundation, ID Biomedical Corporation of WashingtonInventors: Mark A. Reddish, Mary ChaoHong Hu, Michael A. Walls, James B. Dale
-
Patent number: 7262024Abstract: The present invention relates to polypeptides of Streptococcus pneumoniae which may be used for prophylaxis, diagnostic and/or therapy purposes.Type: GrantFiled: December 20, 2002Date of Patent: August 28, 2007Assignee: ID Biomedical CorporationInventors: Josée Hamel, Nathalie Charland, Bernard R. Brodeur, Denis Martin, Normand Blais, Catherine Ouellet, Steve Labbe
-
Patent number: 7255867Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.Type: GrantFiled: November 13, 2003Date of Patent: August 14, 2007Assignees: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical ResearchInventors: George H Lowell, George L White, Michael R Batzloff, David S Burt, Tomas B Leanderson, Michael F Good
-
Patent number: 7247308Abstract: The present invention relates to antigens, more particularly an antigen of Streptococcus pygenes (also called group A Streptococcus (GAS)) bacterial pathogen which is useful as vaccine component for therapy and/or prophylaxis.Type: GrantFiled: July 6, 2001Date of Patent: July 24, 2007Assignee: ID Biomedical CorporationInventors: Denis Martin, Josee Hamel, Bernard Brodeur, Stephane Rioux, Martine Boyer